Platform Targets Root Causes of Disease to Drive Drug Discovery with Vin Singh Bullfrog AI

Vin Singh, Founder, Chairman, and CEO of Bullfrog AI, is applying proprietary AI technology to drug development, with a focus on drug target discovery and phase three clinical trials. The company's platform is derived from the Johns Hopkins University Applied Physics Lab and is designed to pinpoint drug targets, identify the root causes of disease, and match patients to appropriate treatments based on genetic profiles. Bullfrog AI aims to reduce clinical trial timelines, improve success rates, identify more accurate biomarkers, and improve patient outcomes. Vin explains, "We are in the AI innovator category, and we're applying our proprietary platform to the challenges that exist in the world of drug development for pharmaceutical and biotech companies. Primarily our focus is on the first and the last stage of that process. So the first stage is what you call drug target discovery. So when you take a medication, it targets something in your body. So we're trying to identify novel targets that we believe are the root cause of certain diseases. And then we are also focused on the final stage, which is phase three clinical trials. That's where we have our experience. And that's obviously a very critical and pivotal point in the process and the final stage of a long 10- to 15-year, one- to two-billion-dollar drug development process."   "You need to have the right tool for a certain problem and then data, and they go together. I think on the data side, getting access to rich, deep data sets is critical. And fortunately, the cost to generate that type of data has come down pretty significantly over the past, say, 10 years. So now, for example, we have a project where we have brain data, and it's the type of data where you can really make discoveries and insights and so forth. And so that's a really critical part of this process. The other part is: what tool do you have, and what problem are you trying to solve? Our technology is unique. I'd say most companies use technology that comes from NVIDIA and AWS. So they're all kind of using the same tools from the same toolbox." "Our technology comes from Johns Hopkins University Applied Physics Lab, which is a world-renowned institution. We have IP around our platform, and we've continued to innovate over the years. It definitely has unique capabilities, and it is specifically designed for the types of problems that exist in drug development." #BullFrogAI $BFRG, #AI, #AIinBiotech, #MachineLearning, #DrugDevelopment #AIinHealthcare #PrecisionMedicine #Neuropsychiatry #Oncology #DigitalHealth #ClinicalTrials #Biomarkers #bfLEAP bullfrogai.com Download the transcript here